The release late Friday, May 22, of clarified rules on the Paycheck Protection Program (PPP) cleared up some aspects of the program, left some others uncertain but also drove home the point that for the first recipients, the end of the money isn't that far away.The primary purpose of the clarification issued by the U.S. Small Business Administration (SBA) was to reiterate earlier interim rules about qualifications and payback provisions for the PPP, which was designed to allow companies to help keep employees on the payroll rather than on the unemployment rolls. As the SBA rule released on May 22 notes, the eligible costs covered by PPP were to compensate for eight weeks of payroll expenses. With the first funds disbursed under the PPP on April 3, the 56-day period of payroll protection could be ending later this week for the first batch of recipients.The PPP has been cited by some trucking...
In the first-quarter, Target posted a beat on both its top and bottom line. The retail giant also saw a spike in digital comparable sales up 141%. Yahoo Finance's Brian Sozzi and Alexis Christoforous speak to Brian Cornell, Target chairman & CEO about the current state of the business and the future outlook of the store, including the importance of safety....
Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani speak with Novavax R&D President Dr. Gregory Glenn about the company’s coronavirus vaccine candidate. ...
Merck & Co. (MRK) on Tuesday became the latest drugmaker to join the race for the development of a COVID-19 treatment by announcing the purchase of Austrian vaccine maker Themis Bioscience and the collaboration with non-profit research group IAVI.Shares in Merck rose 4% to $79.40 in U.S. pre-market trading. The drugmaker said that the Themis acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform, and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate. The vaccine candidate is in pre-clinical development, and clinical studies are planned to start later in 2020.In addition, Merck announced a new collaboration with IAVI, a non-profit scientific research organization, to advance the development and global clinical evaluation of another vaccine candidate for the prevention of COVID-19.This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s Ebola...
Semiconductor maker Nvidia (NASDAQ: NVDA) long ago attained story stock status, but the company is adding new chapters to that book this year.The stock is up more than 172% off its March lows, helped by a 27.13% gain over the past month.Nvidia enters Tuesday about $50 billion shy of Intel (NASDAQ: INTC) for the title of largest U.S.-based semiconductor company by market value.With a price tag of $361, Nvidia isn't cheap by that metric and it's rapidly becoming difficult for smaller investors to amass large positions in the name. Enter exchange-traded funds.An interesting thing about Nvidia's relationship with the 232 ETFs in which it resides is that some of the funds with the largest positions in the stock aren't dedicated chip ETFs. Here are a few to consider.Global X Robotics & Artificial Intelligence ETF (BOTZ) The Global X Robotics & Artificial Intelligence ETF (NASDAQ: BOTZ) isn't just one of the largest...